China Biologic Products, Inc. (NASDAQ:CBPO) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $123.33 for the company and are forecasting that the company will post $1.30 earnings per share for the current quarter, according to Zacks. Zacks has also given China Biologic Products an industry rank of 155 out of 265 based on the ratings given to its competitors.

Several analysts recently weighed in on CBPO shares. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. BidaskClub downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th.

Several hedge funds have recently made changes to their positions in the business. FMR LLC lifted its position in shares of China Biologic Products by 9.8% in the 2nd quarter. FMR LLC now owns 2,065,269 shares of the biopharmaceutical company’s stock worth $233,582,000 after acquiring an additional 184,720 shares during the period. BlackRock Inc. lifted its position in shares of China Biologic Products by 694.1% in the 1st quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after acquiring an additional 1,318,183 shares during the period. Hillhouse Capital Management Ltd. lifted its position in shares of China Biologic Products by 186.8% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 753,624 shares of the biopharmaceutical company’s stock worth $85,235,000 after acquiring an additional 490,874 shares during the period. Hermes Investment Management Ltd. lifted its position in shares of China Biologic Products by 9.4% in the 3rd quarter. Hermes Investment Management Ltd. now owns 712,424 shares of the biopharmaceutical company’s stock worth $65,735,000 after acquiring an additional 61,307 shares during the period. Finally, Macquarie Group Ltd. lifted its position in shares of China Biologic Products by 115.3% in the 2nd quarter. Macquarie Group Ltd. now owns 587,587 shares of the biopharmaceutical company’s stock worth $66,456,000 after acquiring an additional 314,700 shares during the period. Institutional investors own 72.82% of the company’s stock.

China Biologic Products (NASDAQ CBPO) opened at 80.06 on Friday. The firm has a 50 day moving average price of $91.34 and a 200-day moving average price of $102.36. China Biologic Products has a 12 month low of $76.26 and a 12 month high of $125.99. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of 20.84 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. During the same quarter in the prior year, the company earned $1.26 EPS. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, equities analysts forecast that China Biologic Products will post $4.93 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Analysts Set $123.33 Target Price for China Biologic Products, Inc. (CBPO)” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/21/analysts-set-123-33-target-price-for-china-biologic-products-inc-cbpo.html.

About China Biologic Products

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.